The Lockhart Lab is interested in informing risk factors and mechanisms that threaten brain health and accelerate cognitive decline. The field of neuroimaging is progressing rapidly and is critical toward the ultimate goals of identifying effective strategies to preserve cognitive function and to treat diseases underlying cognitive impairment. Imaging biomarkers play an essential role in AD diagnosis. By embracing a team-science approach, we substantially contribute to the successful launch of novel MRI modalities, PET radiotracer, and sophisticated statistical analyses for Alzheimer's Disease Research Center (ADRC) research applications.

Through strategic planning, coordination and oversight, we enhance the ADRC’s ability to address themes of 1) understanding transitions from normal aging to mild cognitive impairment (MCI) and AD, by longitudinally characterizing participants with imaging markers of AD and vascular pathology; 2) examining roles of metabolic and vascular factors, by adding innovative vascular imaging with amyloid and tau PET; and 3) understanding how relationships may be modified for under-served groups.

Publications

Wake Forest Alzheimer's Disease Research Center Imaging Biomarker Core Publications

Funding

  • NIA P30 AG072947
  • NIH 2T32AG033534-13
  • AHA 24PRE1200264

Lab Updates

January 2024

  • Sud Krishnamurthy received an American Heart Association (AHA) Award to investigate the Impacts of Neighborhood Disadvantage on ADRD Risks, Imaging Biomarkers, and Cognition.
  • Marc Rudolph presented a talk at the Human Amyloid Imaging 2024 Conference in Miami, FL (January 17 -19, 2024).

Get to Know Us

Sam Lockhart, PhD

Samuel Lockhart, PhD
Lockhart Lab Principal Investigator/Associate Professor, Internal Medicine-Geriatrics/ Wake Forest ADRC Imaging Biomarker Core Co-Leader/ U.S. POINTER Imaging Study Coordinating Center PI

Research Interests: Dr. Lockhart conducts cutting-edge research in neuroimaging within the framework of our ADRC, OAIC, and CHAAP, with a focus on metabolic, vascular, and neuropathological processes in the aging/AD continuum. His research spans translational models of disease. His work has furthered understating of how tau and beta-amyloid interact in Alzheimer’s disease and how cardiometabolic risk factors affect brain health. His work has been published in major journals and represents important advances towards identifying potential paths to slowing cognitive decline. His understanding of the interplay of complex imaging biomarkers in brain and cognitive research has resulted in successful extramural grants (R01s, R21s, R24s), demonstrating the originality and impact of his research.

What made you interested in the neuroscience/Alzheimer’s Disease field? Alzheimer’s Disease is the moonshot of our time. We are looking at problems that we have never faced, and coming up with ways to understand and tackle these issues interests me. You will never become bored in this field as there is constant, daily intellectual stimulation

Top 3 phone apps: Remind, Facebook, GuitarTuna

Places you’d love to visit: Argentina, Panama, Cuba, South Korea

Lockhart Lab Throughout the Years

image text

2021

image text

2022

image text

2022

image text

2023

image text

2023

image text

2023

2021
2022
2022
2023
2023
2023